Effect of natural killer T cell activation on initiation of atherosclerosis

Summary

It has been shown that natural killer T (NKT) cell activation accelerates atherosclerosis in apoE^−/− mice. ApoE is,however,an important mediator in the presentation of lipids which may complicate conclusions on the role of NKT cells in atherosclerosis. Treatment of LDLr^−/− mice with α-GalCer during Western-type diet feeding is therefore of interest. Atherosclerosis was induced by Western-type diet feeding and collar placement around the carotid arteries in both LDLr^−/− and apoE^−/− mice. Subsequently, the mice were treated twice a week with α-GalCer. This resulted in an 84% reduction in plaque size in LDLr^−/− mice (P<0.05), while no effect was observed in apoE^−/− mice. In-vitro incubation of splenocytes with α-GalCer showed that LDLr^−/− splenocytes proliferated stronger than apoE^−/− splenocytes. This is reflected in a larger increase in production of cytokines and especially IL-10 after in-vitro stimulation with α-GalCer in LDLr^−/− mice compared with apoE^−/− splenocytes. Additionally, feeding a Western-type diet for 1.5 weeks induced a strong increase in the number of NKT cells in LDLr^−/− mice and this increase was slower and less prominent in apoE^−/− mice. Administration of α-GalCer to LDLr^−/− mice in combination with Western-type diet feeding reduced plaque formation, but this effect was not seen in apoE^−/− mice. This may be explained by the decreased presentation of lipids on CD1d molecules due to the lack of apoE. In this study we proved for the first time that NKT cells may also act in an atheroprotective manner.

Keywords

Atherosclerosis - cytokines - immune response - NKT cells

• References

• 1 Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004; 22: 361-403.
• 2 Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. Jul 2006; 06: 508-519.
• 3 Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989; 135: 169-175.
• 4 Stemme S, Faber B, Holm J. et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 1995; 92: 3893-3897.
• 5 Robertson AK, Hansson GK. T cells in atherogenesis: for better or for worse?. Arterioscler Thromb Vasc Biol 2006; 26: 2421-2432.
• 6 Young JL, Libby P, Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 2002; 88: 554-567.
• 7 Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003; 163: 1117-1125.
• 8 van Wanrooij EJ, van Puijvelde GH, de Vos P. et al. Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 204-210.
• 9 King VL, Szilvassy SJ, Daugherty A. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor−/− mice. Arterioscler Thromb Vasc Biol 2002; 22: 456-461.
• 10 Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001; 413: 531-534.
• 11 Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost 2007; 97: 714-721.
• 12 Franitza S, Grabovsky V, Wald O. et al. Differential usage of VLA-4 and CXCR4 by CD3+CD56+ NKT cells and CD56+CD16+ NK cells regulates their interaction with endothelial cells. Eur J Immunol 2004; 34: 1333-1341.
• 13 Bobryshev YV, Lord RS. Co-accumulation of dendritic cells and natural killer T cells within ruptureprone regions in human atherosclerotic plaques. J Histochem Cytochem 2005; 53: 781-785.
• 14 Bobryshev YV, Lord RS. Identification of natural killer cells in human atherosclerotic plaque. Atherosclerosis 2005; 180: 423-427.
• 15 Nakai Y, Iwabuchi K, Fujii S. et al. Natural killer T cells accelerate atherogenesis in mice. Blood 2004; 104: 2051-2059.
• 16 Tupin E, Nicoletti A, Elhage R. et al. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med 2004; 199: 417-422.
• 17 Major AS, Wilson MT, McCaleb JL. et al. Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24: 2351-2357.
• 18 Ostos MA, Recalde D, Zakin MM. et al. Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic inflammation. FEBS Lett 2002; 519: 23-29.
• 19 Aslanian AM, Chapman HA, Charo IF. Transient role for CD1d-restricted natural killer T cells in the formation of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2005; 25: 628-632.
• 20 Vanderlaan PA, Reardon CA, Sagiv Y. et al. Characterization of the natural killer T-cell response in an adoptive transfer model of atherosclerosis. Am J Pathol 2007; 170: 1100-1107.
• 21 Hong S, Wilson MT, Serizawa I. et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001; 07: 1052-1056.
• 22 Jahng AW, Maricic I, Pedersen B. et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med 2001; 194: 1789-1799.
• 23 Saubermann LJ, Beck P, De Jong YP. et al. Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology 2000; 119: 119-128.
• 24 Singh N, Hong S, Scherer DC. et al. Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol 1999; 163: 2373-2377.
• 25 Burdin N, Brossay L, Kronenberg M. Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol 1999; 29: 2014-2025.
• 26 van den Elzen P, Garg S, Leon L. et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 2005; 437: 906-910.
• 27 von der Thusen JH, van Berkel TJ, Biessen EA. Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation 2001; 103: 1164-1170.
• 28 Kawano T, Cui J, Koezuka Y. et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278: 1626-1629.
• 29 Ortaldo JR, Young HA, Winkler-Pickett RT. et al. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCRbinding ceramides. J Immunol 2004; 172: 943-953.
• 30 Karussis D, Michaelson DM, Grigoriadis N. et al. Lack of apolipoprotein-E exacerbates experimental allergic encephalomyelitis. Mult Scler 2003; 09: 476-480.
• 31 Jahng A, Maricic I, Aguilera C. et al. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 2004; 199: 947-957.
• 32 Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
• 33 Pinderski LJ, Fischbein MP, Subbanagounder G. et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptordeficient Mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002; 90: 1064-1071.
• 34 Von Der Thusen JH, Kuiper J, Fekkes ML. et al. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr−/− mice. Faseb J 2001; 15: 2730-2732.
• 35 Boullier A, Bird DA, Chang MK. et al. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann NY Acad Sci 2001; 947: 214-223.
• 36 Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008; 08: 802-815.